Trial
NCT04050462
Nivolumab Combined With BMS-986253 in HCC Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks
Why stopped
Study was terminated early by the drug sponsor due to slow accrual and a change in the company's drug development priorities
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-16